Aptevo Therapeutics (NASDAQ:APVO) Downgraded by Wall Street Zen to Sell

Wall Street Zen downgraded shares of Aptevo Therapeutics (NASDAQ:APVO) from a hold rating to a sell rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (e)” rating on shares of Aptevo Therapeutics in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Aptevo Therapeutics has a consensus rating of “Hold”.

Aptevo Therapeutics Stock Performance

Shares of APVO stock opened at $4.51 on Friday. Aptevo Therapeutics has a fifty-two week low of $3.95 and a fifty-two week high of $1,299.60. The stock has a 50 day simple moving average of $7.00 and a two-hundred day simple moving average of $17.78. The company has a market cap of $4.51 million, a P/E ratio of 0.00 and a beta of 1.44.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Virtu Financial LLC acquired a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned approximately 1.16% of Aptevo Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 8.06% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.